肾移植术后早期淋巴细胞及DSA监测在诊断移植排斥反应中的意义
Significance of lymphocytes and DSA monitoring for acute rejection diagnosis on the early stage of kidney transplantation

DOI: 10.6040/j.issn.1671-7554.0.2016.1307

Keywords: 肾脏移植,淋巴细胞,非供者特异性抗体,供者特异性抗体,免疫状态监测,
Lymphocyte,Non-donor specificity antibodies,Renal transplant,Immune state monitoring,Donor specificity antibodies

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Haas M. The revised(2013)Banff Classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations[J]. Am J Transplant, 2016, 16(5):1352-1357.
[2]	Kanzaki G, Shimizu A. Currently available useful immunohistochemical markers of renal pathology for the diagnosis of renal allograft rejection[J]. Nephrology, 2015, 20(2):9-15.
[3]	Little CC, Tyzzer EE. Further experimental studies on the inheritance of susceptibility to a transplantable tumor, carcinoma(J. W. A.)of the Japanese waltzing mouse[J]. J Med Res, 1916, 33(3): 393-453.
[4]	Suthanthiran M, Strom TB. Mechanisms and management of acute renal allograft rejection[J]. Surg Clin North Am, 1998, 78(1):77-94.
[5]	Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes:dying to survive[J]. Adv Chronic Kidney Dis, 2016, 23(5): 281-286.
[6]	Strom TB, Garovoy MR. Clinical and experimental aspects of renal allograft rejection[J]. Am J Kidney Dis, 1981, 1(1): 5-14.
[7]	Nashan B. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?[J]. Transplant Rev, 2009, 23(1):47-52.
[8]	McKeown-Eyssen GE, Guttmann RD. Factors associated with outcome of renal transplantation[J]. Can Med Assoc J, 1983, 129(11): 1195-1199.
[9]	Bravo Soto JA, Esteban de la Rosa RJ, Luna del Castillo JD, et al. Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients[J]. Transplant Proc, 2003, 35(4): 1355-1359.
[10]	Ordonez L, Bernard I, Chabod M, et al. A higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45RC expressed by the recipients’ CD8 T cells[J]. PLoS One, 2013, 8(7): e69791. doi: 10.1371/journal.pone.0069791.
[11]	McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation[J]. Transplantation, 2000, 69(3): 319-326.
[12]	Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes[J]. Transplantation, 2013, 95(9): 1113-1119.
[13]	Sacks SH, Zhou W. The role of complement in the early immune response to transplantation[J]. Nat Rev Immunol, 2012, 12(6): 431-442.
[14]	Alexandre L, Carmen L, Dewi V, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013, 369(13): 1215-1227.
[15]	Loupy A, Haas M, Solez K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41.
[16]	Little CC. The heredity of susceptibility to a transplantable sarcoma(J. W. B.)of the Japanese waltzing mouse[J]. Science, 1920, 51(1323): 467-468.
[17]	Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients[J]. Transplant Rev, 2017, 31(1):47-54.
[18]	Rajalingam R. The impact of hla class I-specific killer cell immunoglobulin-like receptors onantibody-dependent natural killer cell-mediated cytotoxicity and organ allograft rejection[J]. Front Immunol, 2016, 7:585. doi: 10.3389/fimmu.2016.00585.
[19]	Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches[J]. Am J of Transplant, 2014,14(2): 255-271.
[20]	Salvadori M, Bertoni E. Impact of donor-specific antibodies on the outcomes of kidney graft: pathophysiology, clinical, therapy[J]. World J Transplant, 2014, 24(1): 1-17.
[21]	Harmer AW, Koffman CG, Heads AJ, et al. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections[J]. Transplant Proc, 1995, 27(1): 666-667.
[22]	郑瑾,薛武军,景鑫,等. 供者特异性抗体监测在肾脏移植中的应用[J]. 中华移植杂志(电子版), 2014, 8(3): 133-137. ZHENG Jin, XUE Wujun, JING Xin, et al. Donor specific antibodies monitoring in the kidney transplantation[J]. Chin J Transplant(Electronic Edition), 2014, 8(3): 133-137.
[23]	杨勇,王伟,司晶,等. 供者特异性抗体在肾移植中的诊治进展[J]. 武汉大学学报(医学版), 2016, 37(4): 640-646. YANG Yong, WANG Wei, SI Jing, et al. Current diagnosis and therapy states of donor specific antibodies in kidney transplantation[J]. Medical Journal Wuhan University, 2016, 37(4): 640-646.
[24]	Haas M. The revised(2013)Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations[J]. Am J Transplant, 2016, 16(5): 1352-1357.
[25]	Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo Donor-Specific HLA antibodies identify pediatric kidney recipientsat risk for late antibody-mediated rejection[J]. Am J of Transplant, 2012, 12(12): 3355-3362.
[26]	El-Awar N, Terasaki P, Lazda V, et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies[J]. Transplant Proc, 2002, 34(7): 2531-2532.
[27]	Zheng J, Xue W, Jing X, et al. Influence of de novo donor-specific antibody on early renal allograft function recovery[J]. Ren Fail, 2015, 37(3): 462-468.
[28]	Thammanichanond D, Mongkolsuk T, Rattanasiri S, et al. Significance of C1q-fixing donor-specific antibodies after kidney transplantation[J]. Transplant Proc, 2014, 46(2): 368-371.

Full-Text